Interleukin-15 Administration Improves Diaphragm Muscle Pathology and Function in Dystrophic mdx Mice
- 30 April 2005
- journal article
- Published by Elsevier in The American Journal of Pathology
- Vol. 166 (4) , 1131-1141
- https://doi.org/10.1016/s0002-9440(10)62333-4
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- New therapies for muscular dystrophy: cautious optimismTrends in Molecular Medicine, 2004
- Update on therapies for sarcopenia: novel approaches for age-related muscle wasting and weaknessExpert Opinion on Therapeutic Patents, 2004
- Administration of insulin‐like growth factor‐I improves fatigue resistance of skeletal muscles from dystrophic mdx miceMuscle & Nerve, 2004
- Pharmacological strategies for muscular dystrophyNature Reviews Drug Discovery, 2003
- Helper (CD4+) and Cytotoxic (CD8+) T Cells Promote the Pathology of Dystrophin-Deficient MuscleClinical Immunology, 2001
- Interleukin-15 Stimulates C2 Skeletal Myoblast DifferentiationBiochemical and Biophysical Research Communications, 1997
- Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity.Journal of Clinical Investigation, 1997
- No alteration in gene expression of components of the ubiquitin proteasome proteolytic pathway in dystrophin-deficient musclesFEBS Letters, 1996
- Interleukin-15: a novel anabolic cytokine for skeletal muscleEndocrinology, 1995
- Cloning of a T Cell Growth Factor that Interacts with the β Chain of the Interleukin-2 ReceptorScience, 1994